Best Clinical Genomics Companies in Massachusetts, United States

Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.

4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.

Funding rounds

• May 2026Series B—
• May 2023Series B$13M
• Jul 2020Series A$4.1M

Founders & team

Rodrigo NavarroCo-Founder & CEO & PresidentSupratim RayCo-Founder & CIOTathagata DasguptaFounder

Tech stack

AosAzureBootstrapCdnjsCloudflareCookieyes

Provider of a diagnostic platform for DNA and RNA detection. The company has developed proprietary CRISPR-based SHERLOCK and synthetic biology-based INSPECTR technologies to create diagnostic tools for the detection of infectious disease, early detection of cancer, treatment monitoring, and precision medicine.

Funding rounds

• Jun 2025Grant (prize money)$130.3K
• Aug 2024Grant (prize money)$298.9K
• Jul 2023Grant (prize money)$175K
• Nov 2022Grant (prize money)$2M

Founders & team

David WaltCo-FounderOmar AbudayyehCo-FounderJonathan GootenbergCo-Founder

Investors

Open Philanthropy, Novalis LifeSciences, Illumina Ventures, Albany Capital, Good Ventures, Northpond Ventures

Developer of RNA-based therapeutics for multiple disorders. It is building compound libraries likely to recognize the RNA target sites and modulate their function, particularly those mediated by the regulatory proteins. The data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation.

Funding rounds

• 2025Series A—
• Nov 2022Series A$52M
• May 2021Seed$18M
• Sep 2020Grant (prize money)$400K

Founders & team

Zhiping WengCo-FounderSimon XiCo-Founder and CEOTravis WagerCo-Founder

Investors

Boehringer Ingelheim Venture Fund, Matrix Partners China, AstraZeneca, Delos Capital, Matrix, Lilly Asia Ventures

Provider of precision medicine based on liquid biopsy test. The company's platform identifies which drug will work based on the patient's fundamental blood test report. It offers PrismRA is a blood-based test that predicts patients respond to anti-TNF therapy before the drug is prescribed. The company focuses on autoimmune, neurological, and cardiovascular diseases.

Funding rounds

• May 2024Series D$5.8M
• Feb 2022Series D$110M
• Mar 2021Series C$82M
• Feb 2020Series B—

Founders & team

Joseph LoscalzoCo-FounderAlbert-Laszlo BarabasiCo-FounderMarcell VeidnerCo-Founder

Investors

Optum Ventures, aMoon, Northpond Ventures, Echo Health Ventures, Khosla Ventures, Alumni Ventures

Tech stack

WordpressMysqlPhpNginxJquery MigrateJquery

Developer of microbiome therapeutics to treat a wide range of diseases. The product pipeline includes SER-109 for C. difficile infection (CDI), SER-155 for antibiotic-resistant infections and GvHD, and SER 287 for ulcerative colitis.

Funding rounds

• 2024Post IPO—
• Nov 2017Grant (prize money)$2.5M
• Dec 2014Series D$65M
• Nov 2014Series C$48M

Founders & team

David BerryFounderEric ShaffPresident

Investors

Enso Ventures, Alexandria, Flagship Pioneering, Mayo Clinic Business Accelerator, CARB-X, Nestlé Health Science

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Developer of multimodal molecular diagnostic platform for early disease detection. It focuses on creating diagnostic solutions, particularly for cancer, by integrating molecular biology and engineering. The company's platform aims to provide accurate and accessible diagnostics to empower patients and healthcare providers. It develops and commercializes a diagnostic platform that utilizes multimodal detection to identify disease biomarkers. The company collaborates with scientists, engineers, and clinicians to ensure its diagnostic platform meets patient care standards.

Funding rounds

• Aug 2025Grant (prize money)$329.7K
• Apr 2025Grant (prize money)$756K
• Jan 2025Grant (prize money)$756K
• Sep 2023Grant (prize money)$329.7K

Founders & team

Reza MollaaghababaCo-FounderRich DevitoCo-FounderRoya Khosravi-FarCo-Founder & CEO

Investors

HHS

Provider of genomics data analysis platform for healthcare. The company has developed an integrated platform for the analysis, interpretation, and reporting of NGS data for diagnosis. The diagnostic platform uses whole-genome sequencing (WGS) data generated through collaboration with sequencing partners, automated data analysis with clinical report generation, and interpretation to provide a comprehensive molecular diagnostic service for a wide range of disease areas.

Funding rounds

• Apr 2024Series C$36M
• Oct 2023Series C—
• Oct 2022Conventional Debt$21M
• Feb 2022Series C$41.5M

Founders & team

Haim NeermanCo-Founder & CEOTomer JackmanCo-Founder

Investors

GF Financial Markets, Quark Venture, IBM, Pitango, New Era Capital Partners, 20/20 HealthCare Partners

Tech stack

All In One SeoAmazon Web ServicesApple Icloud MailAutoptimizeCart FunctionalityCloudflare

Provider of blood tests for early cancer detection. The company provides blood-based tests for their detection. The company offers a liquid biopsy test NavDx, that measures fragments of DNA or the circulating tumor DNA shed by cancers cells in the blood.

Funding rounds

• Jun 2024Series A$17.5M
• Sep 2022Series A$33.4M
• Mar 2020Series A$17M
• Sep 2019Seed$650K

Founders & team

Piyush GuptaFounder & CEO

Investors

Gurnet Point Capital, TechU, BrightEdge, MIT Alumni Angels of Boston

Tech stack

Amazon AlbAmazon CloudfrontAmazon Web ServicesAnime.JsApple Icloud MailBootstrap

Neurogenetic medicine innovator, developing transformative treatments for neurological diseases. This biotechnology company leverages human genetics to modify and cure neurological diseases. The company focuses on genetic medicines for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other central nervous system diseases. Revolutionizing delivery across the blood-brain barrier is a key focus, utilizing a proprietary AAV capsid discovery platform to generate novel capsids. The company aims to advance its pipeline by achieving preclinical and clinical milestones, establishing proof-of-biology and proof-of-concept. The goal is to transform the treatment of neurological diseases, creating disease-modifying neurogenetic medicines by identifying validated targets and advancing multiple therapeutic modalities. The company is dedicated to making transformative treatments and cures available to those afflicted with neurological diseases.

Funding rounds

• Jan 2024Post IPO$20M
• Mar 2023Post IPO$39M
• Jan 2019Post IPO$50M
• Apr 2015Series B$60M

Founders & team

Steven PaulCo-FounderAl SandrockCEO

Investors

Neurocrine, Third Rock Ventures, Brookside Capital, Wellington, Casdin Capital, PFM Health Sciences

Developer of non-invasive diagnostic technology for the detection of bladder cancer. It offers atomic force microscopy imaging and a machine learning modeling platform that quantifies biomarkers on cell surfaces of samples.

Developer of genome sequencing-based diagnostics for infectious diseases. The company offers diagnostic solutions based on machine learning and genomics for infectious diseases. The assay includes Blood2Bac and BacDetect that uses whole-genome sequencing to identify both infecting species and drug resistance in bacterial infections.

Funding rounds

• Sep 2023Series B$16M
• Aug 2023Grant (prize money)$300K
• Oct 2022Grant (prize money)$8.2M
• Feb 2022Series B$21M

Founders & team

Jong LeeCEO & Cofounder

Investors

CARB-X, NIH, NIAID, Golden Seeds, Sands Capital Ventures, Triventures

Tech stack

WordpressMysqlPhpVimeoGravity FormsYoast Seo